Noveltreat 1.7 mg Pre-filled Pen
Dosage
Starting at just
$114.53
In stock
Only %1 left
SKU
CMS8989
What is Noveltreat 1.7 mg Pre-filled Pen
Noveltreat 1.7 mg Pre-filled Pen contains the FDA-approved active ingredient Semaglutide base (1.7 mg/0.75 ml). It is a Glucagon-like Peptide-1 (GLP-1) receptor agonist indicated for enhanced glycemic control in adults for chronic weight management in people with Obesity or Overweight-related health conditions.
Semaglutide binds to and activates GLP-1 receptors in the pancreas and brain. This triggers glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes a sustained feeling of fullness.
Sun Pharmaceutical Industries Ltd manufactures Noveltreat 1.7 mg Pre-filled Pen in GMP-compliant facilities. The pre-filled pen is designed for once-weekly self-injection under the skin (subcutaneously) of the thigh, abdomen, or upper arm. It can be administered at any time of the day, regardless of meals.
Injection sites should be rotated weekly to reduce the likelihood of skin reactions at the same location. To preserve the medication's integrity, store it in a refrigerator at 2°C-8°C, but do not freeze it.
Common side effects of Noveltreat 1.7 mg include nausea and diarrhea, which are usually mild and temporary. Seek immediate medical attention if persistent symptoms such as severe abdominal pain develop, as this could be a sign of Pancreatitis.
Avoid using the injection during pregnancy or breastfeeding as it can harm the baby. Limit alcohol intake, as it can worsen gastrointestinal effects or increase the risk of low blood sugar.
What are the benefits of taking Noveltreat 1.7 mg Pre-filled Pen
Noveltreat 1.7 mg Pre-filled Pen offers significant clinical advantages for patients who require a higher dose of Semaglutide for optimal disease management. Some of the benefits include:
- Enhanced glycemic control: Semaglutide supports reductions in fasting and post-meal blood glucose, helping achieve better hemoglobin A1c (HbA1c) control for patients whose lower doses were insufficient.
- Weight reduction: It supports weight loss, making it especially beneficial for patients managing Obesity or weight-related health conditions.
- Heart health support: Noveltreat 1.7 mg is indicated for overweight or obese adults with pre-existing cardiovascular disease, with clinical evidence showing reduced risk of heart attack, Stroke, and cardiovascular death.
- Appetite and craving management: Semaglutide exerts stronger central effects on appetite-regulating pathways at this dose, helping maintain dietary adherence over the long term.
How to take Noveltreat 1.7 mg Pre-filled Pen
Noveltreat 1.7 mg Pre-filled Pen is a prescription-only injectable medication. Use it strictly as directed by a healthcare professional. The general guidelines are as follows:
- Administer as a once-weekly subcutaneous injection on the same chosen day each week.
- Remove the pen from the refrigerator a few minutes before use to allow it to reach room temperature. Inject into the abdomen, thigh, or upper arm, rotating the injection site with every dose.
- This injection can be administered at any time of the day, regardless of food intake. However, small, light meals can prevent nausea.
- Do not administer more than one dose within seven days or exceed the prescribed dosage.
Strengths and Substitutes
Noveltreat Pre-filled Pen is currently available in a single strength at Cheap Medicine Shop. However, the following effective alternatives are available:
| Wegovy 0.5 mg | $270.58/injection |
| Wegovy 0.25 mg | $270.58/injection |
| Wegovy 1 mg | $270.58/injection |
What are the side effects of Noveltreat 1.7 mg Pre-filled Pen
Like any medication, Noveltreat 1.7 mg Pre-filled Pen can cause side effects, especially when starting this medicine. Most are temporary and ease as the body adjusts. However, consult a healthcare professional if they persist or worsen:
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Constipation
- Burping or acid reflux
- Fatigue
Safety Advice
Liver Disease
Noveltreat 1.7 mg should be used with caution in people with mild to moderate liver issues. Use in severe impairment is not recommended without a thorough medical evaluation, as reduced liver function can affect medication tolerability and metabolic response. Consulting a doctor before use is vital.
Kidney Impairment
It should be used only if prescribed by a doctor and under medical supervision in case of kidney disease. Regular monitoring is advisable to ensure safety.
Pregnant and Breastfeeding women
Noveltreat 1.7 mg must not be used during pregnancy. Semaglutide has been associated with fetal harm in preclinical studies, and its safety in human pregnancies has not been established. Discontinue treatment and consult a doctor immediately if pregnancy occurs during therapy. Use of this medication while breastfeeding is also not advised. Reliable contraception is strongly recommended throughout the duration of treatment.
Avoid
The injection is contraindicated in individuals with known hypersensitivity to Semaglutide or other inactive ingredients. Avoid use in patients with a personal or family history of Medullary Thyroid Carcinoma (thyroid gland cancer) or Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2), which is an inherited genetic condition that causes tumors in endocrine glands. Avoid concurrent use of other injectable GLP-1 Receptor Agonists.
FAQs
What are the common side effects of Noveltreat 1.7 mg?
The most commonly reported side effects of Noveltreat injection are nausea, vomiting, diarrhea, and constipation. These are particularly common when first moving to this dose from a lower strength. Symptoms are mostly mild to moderate and tend to lessen within a few weeks as the body adapts to the medicine.
When is the best time to take this injection?
Noveltreat 1.7 mg can be administered at any time, with or without food. However, it is important to administer the injection on that same day every week. If a change in injection day is needed, ensure a gap of at least 2 days from the previous dose.
Who should not use Noveltreat 1.7 mg?
Noveltreat 1.7 mg is not appropriate for individuals with a personal or family history of Medullary Thyroid Carcinoma or MEN 2 Syndrome, or those with a known allergy to Semaglutide. It is not indicated for Type 1 Diabetes, Diabetic Ketoacidosis, or use during pregnancy or breastfeeding.
Is Noveltreat safe during pregnancy?
No, Noveltreat 1.7 mg is not safe for use during pregnancy. Animal studies have demonstrated potential risks to fetal development with Semaglutide, and its safety in human pregnancies has not been confirmed. If pregnancy occurs during treatment, stop the injection and seek medical advice immediately.
Does Noveltreat 1.7 mg Pre-filled Pen affect eye health?
Yes, Noveltreat 1.7 mg can affect eye health. In animal studies, it was found that in rare cases, Semaglutide can cause vision changes and even blindness due to rapid blood sugar control. If you experience eye-related symptoms, such as blurry vision, seek medical help immediately.
Can Noveltreat 1.7 mg cause thyroid problems?
Yes, it carries a potential risk. In animal studies, Semaglutide at high doses was associated with thyroid C-cell tumors. Whether this risk applies to humans is not yet fully established. As a precaution, Noveltreat is contraindicated in people with a personal or family history of Medullary Thyroid Carcinoma.
What happens if Noveltreat 1.7 mg is stopped suddenly?
Stopping Noveltreat abruptly can lead to a gradual rise in blood sugar levels, causing the appetite to return to pre-treatment levels, with likely weight regain. So, do not discontinue this medication without consulting a doctor.
What's this?
Check "Remember Me" to access your shopping cart on this computer even if you are not signed in.